Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 195 entries
View as:

Diagnostic Study to Identify Sentinel Lymph Nodes in Women With Stage I or Stage II Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00003654 Org: User:
Start: 09/30/97 End: 01/31/00 Due: 01/31/01

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

Phase: N/A Priority: Normal
NCT ID: NCT02117167 Org: User:
Start: 04/23/14 End: 12/31/23 Due: 12/31/24

Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04428047 Org: User:
Start: 02/04/21 End: 01/07/22 Due: 01/07/23

Blood Biomarkers Based Screening for HPV-driven OPC

Phase: N/A Priority: Normal
NCT ID: NCT06528353 Org: User:
Start: 07/31/25 End: 07/31/31 Due: 07/31/32

Combination Chemotherapy in Treating Women With Stage I Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00055679 Org: User:
Start: 08/31/02 End: 06/30/13 Due: 06/30/14

Concordance of the IHC4 Score Performed in Local or Central Laboratory to Endopredict in ER+/HER2- Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04246606 Org: User:
Start: 04/24/20 End: 11/01/23 Due: 11/01/24

Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00005979 Org: User:
Start: 07/22/98 End: 09/01/07 Due: 09/01/08

Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor

Phase: N/A Priority: Normal
NCT ID: NCT02444390 Org: User:
Start: 05/19/15 End: 07/01/22 Due: 07/01/23

Abiraterone Acetate in Molecular Apocrine Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01842321 Org: User:
Start: 07/31/13 End: 07/04/18 Due: 07/04/19

Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients

Phase: N/A Priority: Normal
NCT ID: NCT01254513 Org: User:
Start: 12/09/10 End: 04/27/17 Due: 04/27/18

Radiation Therapy in Treating Older Women Who Are Undergoing Surgery for Stage I or Stage II Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00104702 Org: User:
Start: 07/31/04 End: 03/31/11 Due: 03/31/12

Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment

Phase: N/A Priority: Normal
NCT ID: NCT01564056 Org: User:
Start: 04/12/12 End: 03/31/26 Due: 03/31/27

Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00674414 Org: User:
Start: 04/30/08 End: - Due: -

A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05639413 Org: User:
Start: 07/24/23 End: 07/31/28 Due: 07/31/29

Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy

Phase: N/A Priority: Normal
NCT ID: NCT03697850 Org: User:
Start: 12/14/18 End: 02/15/29 Due: 02/15/30

A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas

Phase: N/A Priority: Normal
NCT ID: NCT02389244 Org: User:
Start: 09/30/14 End: 06/30/25 Due: 06/30/26

Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients

Phase: N/A Priority: Normal
NCT ID: NCT04115007 Org: User:
Start: 06/23/20 End: 02/28/31 Due: 02/28/32

Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24)

Phase: N/A Priority: Normal
NCT ID: NCT02363751 Org: User:
Start: 12/31/14 End: 08/31/20 Due: 08/31/21

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00003860 Org: User:
Start: 09/30/98 End: 09/30/05 Due: 09/30/06

Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.

Phase: N/A Priority: Normal
NCT ID: NCT06450314 Org: User:
Start: 01/25/25 End: 12/15/29 Due: 12/15/30

My Personalized Breast Screening

Phase: N/A Priority: Normal
NCT ID: NCT03672331 Org: User:
Start: 07/18/19 End: 12/31/27 Due: 12/31/28

Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06245356 Org: User:
Start: 03/21/25 End: 10/21/28 Due: 10/21/29

Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT00820547 Org: User:
Start: 01/31/09 End: 09/30/19 Due: 09/30/20

Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02393820 Org: User:
Start: 08/26/13 End: 10/31/19 Due: 10/31/20

Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30)

Phase: N/A Priority: Normal
NCT ID: NCT03333356 Org: User:
Start: 04/19/18 End: 12/31/27 Due: 12/31/28